Literature DB >> 9822070

Antithrombotic therapy in peripheral arterial occlusive disease.

M R Jackson1, G P Clagett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9822070     DOI： 10.1378/chest.114.5_supplement.666s

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  10 in total

Review 1.  Drug-induced thrombocytopenia in the coronary care unit.

Authors:  N M Patnode; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

Review 2.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 3.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

4.  Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Kristina Danielyan; Juan-Carlos Murciano; Kumkum Ganguly; Tatiana Krasik; Ronald P Taylor; Steven Pincus; Steven Jones; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

5.  Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.

Authors:  Michael S Conte; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; Hamid Namini; Lynn Seely
Journal:  J Vasc Surg       Date:  2005-09       Impact factor: 4.268

Review 6.  Diabetic foot ulcers. Pathophysiology, assessment, and therapy.

Authors:  C K Bowering
Journal:  Can Fam Physician       Date:  2001-05       Impact factor: 3.275

Review 7.  Clopidogrel: a review of its use in the prevention of atherothrombosis.

Authors:  B Jarvis; K Simpson
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

8.  Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.

Authors:  Michael S Conte; Todd J Lorenz; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; B Lynn Seely
Journal:  Vasc Endovascular Surg       Date:  2005 Jan-Feb       Impact factor: 1.089

9.  Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.

Authors:  Marc Ruivard; Christine Berger; Abdellaziz Achaibi; Claude Campagne; Pierre Philippe
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

10.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.